The 25 US-listed companies whose business best matches “cancer drugs”, closest first.
| Ticker | Company | Market cap | P/E | FCF yield |
|---|---|---|---|---|
| ONC | BeOne Medicines | $46.30B | 51.7 | 1.9% |
| AZN | AstraZeneca | $289.14B | 38.8 | 3.0% |
| LLY | Eli LillyMatched on Oncology | $1.21T | 42.4 | 0.5% |
| BMY | Bristol-Myers SquibbMatched on Oncology and hematology | $127.02B | 10.0 | 10.1% |
| TAK | Takeda PharmaceuticalMatched on Oncology | $67.16B | 42.0 | 6.0% |
| HCM | HUTCHMED (China) | $2.64B | — | -3.4% |
| EXEL | Exelixis | $16.98B | 19.0 | 4.3% |
| INCY | Incyte | $24.39B | 38.6 | 5.5% |
| GMAB | Genmab A/S | $32.98B | 38.9 | 3.4% |
| SNY | SanofiMatched on Oncology | $112.71B | 9.1 | 7.0% |
| NUVB | Nuvation Bio | $1.47B | — | -12.7% |
| ZLAB | Zai Lab | $3.16B | — | -5.9% |
| RVMD | Revolution Medicines | $41.59B | — | -2.5% |
| ERAS | Erasca | $5.04B | — | -2.6% |
| IDYA | IDEAYA Biosciences | $3.02B | — | -2.7% |
| CELC | Celcuity | $3.27B | — | -4.9% |
| TNGX | Tango Therapeutics | $3.63B | — | -5.6% |
| RCUS | Arcus Biosciences | $2.63B | — | -24.7% |
| VSTM | Verastem | $1.02B | — | -25.2% |
| SMMT | Summit Therapeutics | $13.06B | — | -2.6% |
| JANX | Janux Therapeutics | $1.08B | — | -7.6% |
| IMTX | Immatics | $1.05B | — | -24.3% |
| LEGN | Legend Biotech | $4.55B | — | -3.0% |
| IOVA | Iovance Biotherapeutics | $3.64B | — | -11.7% |
| SLS | SELLAS Life Sciences Group | $1.70B | — | -3.1% |
Matched by what each company does, read from its own business description, so a company can appear for one of its businesses. Updated daily. Not investment advice.